作者
Prasanth Balasubramanian, Shahin Isha, Sadhana Jonna, Lekhya Raavi, Anna Jenkins, Abby Hanson, Emily C Craver, Vikas Bansal, Sean M Caples, Syed Anjum Khan, Nitesh K Jain, Abigail T La Nou, Rahul Kashyap, Rodrigo Cartin-Ceba, Anirban Bhattacharyya, Sanjay Chaudhary, Pramod Guru, Pablo Moreno Franco, Sadia Z Shah, Devang Sanghavi
发表日期
2024/1/1
期刊
Critical Care Medicine
卷号
52
期号
1
页码范围
S251
出版商
LWW
简介
Methods: We performed a retrospective multi-center study on COVID-19 patients admitted to the Mayo Clinic Enterprise health system between March 2020 and June 2022 via Critical Care Medicine VIRUS COVID-19 registry. The outcomes were compared between the subgroups of the cohort divided based on the dose of the dexamethasone (low= 6mg, intermediate= 7-19mg, and high dose= 20mg). Patients were excluded if they were under 18 years, did received a different corticosteroid, or had a different dose of dexamethasone (> 20mg or< 6mg).
Results: A total of 4188 patients were included in our study, of which 2937 (70.2%), 706 (16.8%), and 545 (13%) patients belonged to the low, intermediate, and high dose dexamethasone groups, respectively. The median age of the overall cohort was 65 years, with 60.1% male. High-dose dexamethasone group had lesser age, higher male gender, and higher severity …
学术搜索中的文章
P Balasubramanian, S Isha, S Jonna, L Raavi… - Critical Care Medicine, 2024